You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
開拓藥業-B(09939.HK)於巴拉圭獲得普克魯胺治療COVID-19的首個緊急使用授權
格隆匯 07-16 12:04

格隆匯7月16日丨開拓藥業-B(09939.HK)宣佈,巴拉圭國家公共衞生和社會福利部(MSPBS)於近期正式授予普克魯胺緊急使用授權(EUA),用於MSPBS醫院系統COVID-19住院患者的治療。這是普克魯胺在全球獲得的首個EUA。隸屬於巴拉圭MSPBS醫院系統的Barrio Obrero醫院是獲得EUA許可後首家使用普克魯胺的醫院,患者初步治療效果積極。

普克魯胺是新一代雄激素受體(AR)拮抗劑,目前正在開發用於COVID-19(包括門診患者及住院患者)、前列腺癌及乳腺癌的潛在治療。針對COVID-19治療,集團正在包括美國、南美洲(含巴西)、歐盟、亞洲等國家和地區開展多項註冊性III期全球多中心臨牀試驗(MRCT)。集團將加快推進普克魯胺於其他國家和地區的EUA申請並加速商業化工作。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account